Lineage Cell Therapeutics LCTX
NYSE LCTX
$0.93 +0.03 (+3.33%)
At close: Oct 2, 2026 · 4:00 PM EDT

Lineage Cell Therapeutics (LCTX) Asset Writedowns and Impairment (2010 - 2025)

Updated

Lineage Cell Therapeutics (LCTX) posted Asset Writedowns and Impairment of $14.84 million for FY2025.

Analysis

Lineage Cell Therapeutics (LCTX) Asset Writedowns and Impairment (2010 - 2025) Analysis & Trends

Since FY2009, Lineage Cell Therapeutics has reported Asset Writedowns and Impairment for 8 years.

  • The FY2025 figure stands as the highest annual Asset Writedowns and Impairment in data going back to FY2009.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Lineage Cell Therapeutics 235.20 Mn 33.61 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 14.84 Mn
Dec 31, 2015 1,000.00
Sep 30, 2014 -12,000.00
Jun 30, 2014 12,424.00
Mar 31, 2014 8,576.00
Dec 31, 2013 120.00
Sep 30, 2013 -5,830.00
Jun 30, 2013 -813.00
Mar 31, 2013 1,523.00
Dec 31, 2012 14,684.00
Sep 30, 2012 1,451.00
Jun 30, 2012 3,546.00
Dec 31, 2011 4,906.00
Jun 30, 2011 -2,498.00
Mar 31, 2011 4,008.00
Dec 31, 2010 4,008.00
API Access

Lineage Cell Therapeutics Asset Writedowns and Impairment API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=asset-writedowns-and-impairment&ticker=LCTX&period=max&api_key=YOUR_API_KEY